Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP)

BACKGROUND: In recent times, anti-cancer treatments have focused on Fibroblast Growth Factor (FGF) and Vascular-Endothelial Growth Factor (VEGF) pathway inhibitors so as to target tumor angiogenesis and cellular proliferation. One such drug is Nintedanib; the present study evaluated the effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: da Silva, Raquel Frenedoso, Nogueira-Pangrazi, Ellen, Kido, Larissa Akemi, Montico, Fabio, Arana, Sarah, Kumar, Dileep, Raina, Komal, Agarwal, Rajesh, Cagnon, Valéria Helena Alves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429557/
https://www.ncbi.nlm.nih.gov/pubmed/28499383
http://dx.doi.org/10.1186/s12929-017-0334-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429557/
https://www.ncbi.nlm.nih.gov/pubmed/28499383
http://dx.doi.org/10.1186/s12929-017-0334-z

Ejemplares similares